Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of IV and Oral Olorofim in Healthy Subjects
NCT04207957Phase 1Completed
- Sponsor
- F2G
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olorofim in invasive fungal infection (IFI) (5 arms), sponsored by F2G. Primary endpoints: Maximum Plasma Concentration at 35 days, Area Under the Concentration-Time Curve to Last Quantifiable Concentration at 35 days and 1 more. Started Dec 2019; status: completed.
02
Drugs
olorofim
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT04207957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207957.